| Literature DB >> 35945234 |
Sergey A Dyshlovoy1,2,3, Larisa K Shubina4, Tatyana N Makarieva4, Jessica Hauschild5,6, Nadja Strewinsky5, Alla G Guzii4, Alexander S Menshov4, Roman S Popov4, Boris B Grebnev4, Tobias Busenbender5, Su Jung Oh-Hohenhorst6,7, Tobias Maurer6,8, Derya Tilki6,8, Markus Graefen6, Carsten Bokemeyer5, Valentin A Stonik4, Gunhild von Amsberg5,6.
Abstract
Spongian diterpenes are a group of marine natural compounds possessing various biological activities. However, their anticancer activity is still poorly studied and understood. We isolated six spongian diterpenes from the marine sponge Spongionella sp., including one new spongionellol A and five previously known molecules. The structures were elucidated using a detailed analysis MS and NMR spectra as well as by comparison with previously reported data. Two of them, namely, spongionellol A and 15,16-dideoxy-15α,17β-dihydroxy-15,17-oxidospongian-16-carboxylate-15,17-diacetate exhibited high activity and selectivity in human prostate cancer cells, including cells resistant to hormonal therapy and docetaxel. The mechanism of action has been identified as caspase-dependent apoptosis. Remarkably, both compounds were able to suppress expression of androgen receptor (AR) and AR-splice variant 7, as well as AR-dependent signaling. The isolated diterpenes effectively inhibited drug efflux mediated by multidrug-resistance protein 1 (MDR1; p-glycoprotein). Of note, a synergistic effect of the compounds with docetaxel, a substrate of p-glycoprotein, suggests resensitization of p-glycoprotein overexpressing cells to standard chemotherapy. In conclusion, the isolated spongian diterpenes possess high activity and selectivity towards prostate cancer cells combined with the ability to inhibit one of the main drug-resistance mechanism. This makes them promising candidates for combinational anticancer therapy.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35945234 PMCID: PMC9363487 DOI: 10.1038/s41598-022-17447-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
NMR Data for compound 1 in CDCl3.
| Position | δH (J in Hz) | δC type |
|---|---|---|
| 1α | 0.93, td (13.1, 3.5) | 38.8, CH2 |
| 1β | 1.67, m | |
| 2α | 1.47, m | 18.3, CH2 |
| 2β | 1.62, m | |
| 3α | 1.17, td (13.2, 4.0) | 41.7, CH2 |
| 3β | 1.42, m | |
| 4 | 32.5, C | |
| 5 | 1.30, dd (13.2, 1.8) | 48.2, CH |
| 6α | 1.90, m | 24.6, CH2 |
| 6β | 1.43, m | |
| 7 | 5.45, t (3.0) | 73.4, CH |
| 8 | 51.0, C | |
| 9 | 1.72, m | 44.5, CH |
| 10 | 37.9, C | |
| 11α | 1.71, m | 14.8, CH2 |
| 11β | 1.42, m | |
| 12α | 1.89, m | 19.2, CH2 |
| 12β | 1.73, m | |
| 13 | 2.78, ddd (13.2, 5.2, 2.5) | 37.8, CH |
| 14 | 2.73, dd (5.2, 1.4) | 51.4, CH |
| 15 | 6.16, s | 99.7, CH |
| 16 | 174.2, C | |
| 17 | 6.62, s | 98.8, CH |
| 18 | 0.77, s | 21.2, CH3 |
| 19 | 0.76, s | 33.2, CH3 |
| 20 | 0.85, s | 14.2, CH3 |
| 7-OCO | 2.12, s | 21.4, CH3 |
| 15-OCO | 2.03, s | 21.2, CH3 |
| 17-OCO | 2.13, m | 21.3, CH3 |
| -O | 3.68, s | 52.0, CH3 |
| 7-O | 169.9, C | |
| 15-O | 169.6, C | |
| 17-O | 169.4, C |
Figure 1Diterpenes from marine sponge Spongionella sp. (a), The structures of compounds 1–6. (b), Key COSY (), HMBC () and NOESY () correlations for the new compound 1.
Cytotoxic activity and selectivity of the isolated compounds. IC50s were determined using MTT assay after 48 h of treatment.
| Compound | IC50 [µM] | Mean IC50, cancer cells [µM] | Mean IC50, non-cancer cells [µM] | Selectivity Index (SI) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostate cancer cells | Non-cancer cells | |||||||||||||
| PC3 | PC3-DR | DU145 | DU145-DR | 22Rv1 | VCaP | LNCaP | PNT2 | RWPE-1 | HEK293 | MRC-9 | ||||
| 1 | 0.964 ± 0.11 | 1.23 ± 0.23 | 0.936 ± 0.39 | 1.53 ± 0.16 | 2.64 ± 0.74 | 1.3 ± 0.2 | 1.02 ± 0.57 | 2.21 ± 0.64 | 1.14 ± 0.35 | 22.9 ± 4.4 | 2.19 ± 0.84 | 1.37 | 7.11 | 5.18 |
| 2 | 35.1 ± 5.9 | 34.8 ± 3.5 | 27.9 ± 3.9 | 36.28 ± 8 | 20.9 ± 3.9 | 40.2 ± 7.5 | 8.1 ± 0.7 | 7.5 ± 0.6 | 1.8 ± 0.6 | 2.8 ± 1.1 | 8.4 ± 1.7 | 34.8 | 25.1 | 0.72 |
| 3 | 53.3 ± 9.2 | 84.3 ± 8.3 | 77.9 ± 5.3 | 62.5 ± 10.2 | 40.4 ± 7.2 | 77.6 ± 8.1 | 87.6 ± 4.5 | 34.1 ± 11.9 | 46.7 ± 11.0 | 27.6 ± 7.9 | 54.6 ± 9.0 | 69.1 | 40.7 | 0.59 |
| 4 | 30.9 ± 4.3 | 31.9 ± 8.7 | 25.4 ± 9.8 | 26.3 ± 8.1 | 22.6 ± 3.2 | 32.1 ± 9.9 | 31.7 ± 5.5 | 13.8 ± 7.5 | 23.4 ± 5.7 | 12.5 ± 2.7 | 33.3 ± 4.1 | 28.7 | 20.8 | 0.72 |
| 5 | 2.51 ± 0.93 | 3.63 ± 0.69 | 1.52 ± 0.87 | 1.92 ± 0.16 | 3.22 ± 0.70 | 2.51 ± 1.50 | 1.82 ± 0.85 | 1.59 ± 0.66 | 2.72 ± 0.82 | 4.46 ± 0.46 | 3.13 ± 0.54 | 2.45 | 2.98 | 1.22 |
| 6 | > 100 | > 100 | > 100 | > 100 | 51.8 ± 9.0 | > 100 | > 100 | > 100 | > 100 | 69.5 ± 8.4 | > 100 | 196 | 93.3 | 0.48 |
| Cisplatin | 34.6 ± 8.7 | 4.71 ± 0.86 | 11.7 ± 3.9 | 2.29 ± 0.61 | 0.99 ± 0.65 | 5.02 ± 1.90 | 2.75 ± 0.54 | 9.41 ± 3.2 | 9.02 ± 2.47 | 6.44 ± 2.1 | 6.75 ± 0.48 | 8.40 | 7.91 | 0.94 |
The values are represented as mean ± SD. Selectivity index (SI) was calculated as [mean IC50 in non-cancer cells]/[mean IC50 in cancer cells]. Cisplatin was used as a reference drug.
Figure 2Activity of compounds in 22Rv1 cells determined using trypan blue staining assay. Cells were treated for 48 h. The IC50s are represented as mean ± SD.
Figure 3Proapoptotic activity of the isolated diterpenes 1 and 5 in 22Rv1 cells. (a), Analysis of protein expression by Western blotting. The original full-size blots are represented in Supplementary Fig. S18. (b), Flow cytometry analysis of phosphatidylserine externalization using annexin-V/PI double staining. Cells were pretreated with 100 µM of pan-caspase inhibitor z-VAD(OMe)-fmk (+zVAD) or with the vehicle (-zVAD) for 1 h, and then co-treated with the drugs for another 48 h. Anisomycin (Aniso, 10 µM) was used as a positive control. (c), Flow cytometry analysis of DNA fragmentation in the cells treated with the investigated compounds for 48 h. Cisplatin (Cis, 10 µM) was used as a positive control. *p < 0.05, one-way ANOVA test.
Figure 4Effect on activity of p-glycoprotein (p-gp). (a), Western blotting analysis of p-gp expression in PC3, PC3-DR, as well as in DU145 and DU145-DR cells. The original full-size blots are represented in Supplementary Figure S19. (b), Green fluorescence measured in PC3-DR cells pre-treated with investigated compounds for 30 min and then further incubated with calcein-AM for 15 min. Tariquidar (TQD, 50 nM) was used as a positive control. *p < 0.05, one-way ANOVA test.
Figure 5Effect on p-gp expression and viability of PC3-DR cells. (a), Western blotting analysis of protein expression in PC3-DR cells treated with the indicated concentration of the compounds for 48 h. The original full-size blots are represented in Supplementary Figure S20. (b), Effect on p-gp activity (grey bars) and viability (blue dots) of PC3-DR cells following 30 min exposure to the investigated compounds. p-gp activity was measured using a calcein-AM assay. Cellular viability was measured using MTT assay. Tariquidar (TQD, 50 nM) was used as a positive control. *p < 0.05, one-way ANOVA test.
Figure 6Effects of the drug combinations on viability of PC3-DR and DU145-DR cells. (a), PC3-DR cells were pretreated with tariquidar (TQD, 50 nM) for 30 min and then co-treated with the indicated drugs for 48 h. (b,c), PC3-DR (b) and DU145-DR (c) cells were co-treated with docetaxel (Doce) or cabazitaxel (Caba) in combination with diterpenes 1 or 5 at the indicated concentrations. Cellular viability was measured using MTT assay. The cytotoxicity heat-maps (viability inhibition) as well as synergistic/additive/antagonistic effects of drug combinations were analyzed and visualized using SynergyFinder 2.0 software (https://synergyfinder.fimm.fi/) using a ZIP algorithm (b,c). Red areas indicate synergistic effects of the drug combinations. *p < 0.05, one-way ANOVA test.